Viral Hepatocarcinogenesis

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2010 Mar 16

PMID 20228847

Citations 115

Authors

W-L Tsai

R T Chung

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death worldwide. Despite recent advances in the diagnosis and treatment of HCC, its prognosis remains dismal. Infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are the major risk factors for HCC. Although both are hepatotropic viral infections, there are important differences between the oncogenic mechanisms of these two viruses. In addition to the oncogenic potential of its viral proteins, HBV, as a DNA virus, can integrate into host DNA and directly transform hepatocytes. In contrast, HCV, an RNA virus, is unable to integrate into the host genome, and viral protein expression has a more critical function in hepatocarcinogenesis. Both HBV and HCV proteins have been implicated in disrupting cellular signal transduction pathways that lead to unchecked cell growth. Most HCC develops in the cirrhotic liver, but the linkage between cirrhosis and HCC is likely multifactorial. In this review, we summarize current knowledge regarding the pathogenetic mechanisms of viral HCC.

Citing Articles

Unveiling NUSAP1 as a common gene signature linking chronic HBV infection and HBV-related HCC.

Meng J, Yang Z, Jiang X, Zou J Discov Oncol. 2024; 15(1):61.

PMID: 38441732 PMC: 10914659. DOI: 10.1007/s12672-024-00922-4.

A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma.

Lampimukhi M, Qassim T, Venu R, Pakhala N, Mylavarapu S, Perera T Cureus. 2023; 15(11):e49429.

PMID: 38149129 PMC: 10750138. DOI: 10.7759/cureus.49429.

Microbiota in cancer: molecular mechanisms and therapeutic interventions.

Chen Z, Guan D, Wang Z, Li X, Dong S, Huang J MedComm (2020). 2023; 4(6):e417.

PMID: 37937304 PMC: 10626288. DOI: 10.1002/mco2.417.

An inflammation-related gene landscape predicts prognosis and response to immunotherapy in virus-associated hepatocellular carcinoma.

Gao Y, Li S, Huang Y Front Oncol. 2023; 13:1118152.

PMID: 36969014 PMC: 10033597. DOI: 10.3389/fonc.2023.1118152.

Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.

Papp K, Melosky B, Sehdev S, Hotte S, Beecker J, Kirchhof M Dermatol Ther (Heidelb). 2023; 13(4):867-889.

PMID: 36929121 PMC: 10060504. DOI: 10.1007/s13555-023-00905-3.

References

Ebara M, Fukuda H, Hatano R, Yoshikawa M, Sugiura N, Saisho H . Metal contents in the liver of patients with chronic liver disease caused by hepatitis C virus. Reference to hepatocellular carcinoma. Oncology. 2004; 65(4):323-30. DOI: 10.1159/000074645. View

Yu D, Moon H, Son J, Jeong S, Yu S, Yoon H . Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol. 1999; 31(1):123-32. DOI: 10.1016/s0168-8278(99)80172-x. View

Okabe H, Ikai I, Matsuo K, Satoh S, Momoi H, Kamikawa T . Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology. 2000; 31(5):1073-9. DOI: 10.1053/he.2000.6409. View

Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider P . The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J. 2002; 21(4):525-35. PMC: 125852. DOI: 10.1093/emboj/21.4.525. View

Pinzani M, Milani S, Herbst H, Defranco R, Grappone C, Gentilini A . Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol. 1996; 148(3):785-800. PMC: 1861723. View

Shafritz D, Shouval D, Sherman H, Hadziyannis S, Kew M . Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med. 1981; 305(18):1067-73. DOI: 10.1056/NEJM198110293051807. View

Fujie H, Moriya K, Shintani Y, Yotsuyanagi H, Iino S, Koike K . Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology. 2001; 120(6):1564-5. DOI: 10.1053/gast.2001.24501. View

Baptista M, Kramvis A, Kew M . High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology. 1999; 29(3):946-53. DOI: 10.1002/hep.510290336. View

Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, Shiratori Y . Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol. 2003; 72(1):52-9. DOI: 10.1002/jmv.10545. View

10.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

11.

Gaudio E, Carpino G, Cardinale V, Franchitto A, Onori P, Alvaro D . New insights into liver stem cells. Dig Liver Dis. 2009; 41(7):455-62. DOI: 10.1016/j.dld.2009.03.009. View

12.

Fattovich G . Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003; 23(1):47-58. DOI: 10.1055/s-2003-37590. View

13.

Chen J, Siddiqui A . Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress. J Virol. 2007; 81(12):6757-60. PMC: 1900104. DOI: 10.1128/JVI.00172-07. View

14.

Feitelson M, Lee J . Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 2006; 252(2):157-70. DOI: 10.1016/j.canlet.2006.11.010. View

15.

Tang H, Oishi N, Kaneko S, Murakami S . Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci. 2006; 97(10):977-83. PMC: 11159107. DOI: 10.1111/j.1349-7006.2006.00299.x. View

16.

Cai D, Yuan M, Frantz D, Melendez P, Hansen L, Lee J . Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005; 11(2):183-90. PMC: 1440292. DOI: 10.1038/nm1166. View

17.

Parsons C, Takashima M, Rippe R . Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol. 2007; 22 Suppl 1:S79-84. DOI: 10.1111/j.1440-1746.2006.04659.x. View

18.

Sy S, Wong N, Lai P, To K, Johnson P . Regional over-representations on chromosomes 1q, 3q and 7q in the progression of hepatitis B virus-related hepatocellular carcinoma. Mod Pathol. 2004; 18(5):686-92. DOI: 10.1038/modpathol.3800345. View

19.

Iloeje U, Yang H, Su J, Jen C, You S, Chen C . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3):678-86. DOI: 10.1053/j.gastro.2005.11.016. View

20.

Hassan M, Selimovic D, Ghozlan H, Abdel-kader O . Induction of high-molecular-weight (HMW) tumor necrosis factor(TNF) alpha by hepatitis C virus (HCV) non-structural protein 3 (NS3) in liver cells is AP-1 and NF-kappaB-dependent activation. Cell Signal. 2006; 19(2):301-11. DOI: 10.1016/j.cellsig.2006.07.002. View